image dons

I make a donation

TRANSFUSION-REALITY

Evaluate the impact of transfusion on platelet activation and aggregation, in a series of biological measures (T1 before and T2 after transfusion ) realized in 2 randomized groupes of the REALITY trial (liberal strategy of blood transfusion in patients with a myocardial infarct and anemy compared to a conservative strategy without blood transfusion)

Terminée

La Grande Journée du Coeur (22 juin 2022)
Attention : plus que quelques places restantes !

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Inscriptions ouvertes !

logo étude

objectif

Impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry.

date de réalisation

2016

nombre de patients

93

nombre de centres participants

8 french centers

type de financement

Public (CRC 2016)

Référence

NCT02648113

Impact of Transfusion of Red blood cell on platelet Activation, aggregatioN and Systemic biomarkers with clinical Follow Up Studied in patients with anemia and Myocardial InfarctiON of the REALITY study – (TRANSFUSION-REALITY)

Study Description

Anemia in patients with myocardial infarction (MI) is a relatively frequent issue, resulting in poorer outcome. There is equipoise regarding which transfusion strategy is best, and there is an international consensus on the urgent need for a randomized trial. The REALITY study hypothesize that a "restrictive" transfusion strategy (triggered by Hb <= 8 g/ dL) will be clinically non-inferior to a "liberal" transfusion strategy (triggered by Hb <= 10g/ dL) but will be less costly.
TRANSFUSION-REALITY is a biological ancillary substudy of the REALITY study evaluating impact of RBC transfusion on platelet activation, aggregation and systemic biomarkers of thrombosis and inflammation in a series of biological measurements (baseline at randomization (before the first RBC transfusion (T0)), after RBC transfusion (on the next day after randomization and/or transfusion according to the group (T1)) and at discharge (T2) from the cardiology service.

source clinicaltrials.gov

Autres études

+

ARAMIS

En cours


Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.